Prelude therapeutics provides clinical update and announces presentation of new preclinical data at the upcoming 2022 aacr annual meeting

Announces strategic prioritization within lead programs targeting prmt5 and mcl1

PRLD Ratings Summary

PRLD Quant Ranking